Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (trading symbol: NAOV) on March 14, 2023. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and maintains its principal executive offices in Elmsford, New York.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory disclosure event rather than financial performance results.
Material Changes
The material event reported is the issuance of a press release on March 14, 2023, announcing results from an independent product trial of the Company's product, UroShield. The trial specifically targeted patients with spinal cord injuries. No financial material changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the trial results. The filing explicitly states that the Company undertakes no obligation to update, supplement, or amend the materials attached.
Legal Disclaimer: The information furnished under Item 7.01 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be incorporated by reference into any Securities Act or Exchange Act filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 14, 2023) for specific details on the UroShield trial results.
- Verify the clinical significance of the trial results for patients with spinal cord injuries.
- Confirm the current trading status of NAOV on the Nasdaq Capital Market.
- Note that this filing contains no audited financial statements or forward-looking financial guidance.